Nu-Med Plus (NUMD) Restructuring Costs (2023 - 2024)

Nu-Med Plus (NUMD) reported Restructuring Costs of $300.0 for Q1 2024, down 90.0% sequentially from $3000.0 in Q4 2023.

Nu-Med Plus (NUMD) Restructuring Costs (2023 - 2024) Analysis & Trends

Nu-Med Plus (NUMD) has 2 years of Restructuring Costs data on file, last reported at $300.0 in Q1 2024.

For the quarter ending Q1 2024, Restructuring Costs changed N/A year-over-year to $300.0; the trailing twelve-month figure through Dec 2024 stood at $300.0 (changed N/A YoY), and the FY2025 full-year result was $58.0, down 80.67% from the prior year.
Restructuring Costs declined to $300.0 in Q1 2024, from $3000.0 in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of $3300.0 in Q3 2023 to a low of $300.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	Nu-Med Plus	1.67 Mn	1.67 Mn	-

Download Data